# OnCo record nct07772024 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07772024/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07772024", "NCT07772024" ;
  schema:name "Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma"@en ;
  schema:description "A phase 3 trial of Inobrodib run by CellCentric Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07772024/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07772024> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:drugs <https://onco.cc/drugs/inobrodib/> ;
  onco:companies <https://onco.cc/companies/cellcentric/> .